Childhood cancer survivors tend to have a poor diet during their adult life. This can lead to a higher risk of developing serious illnesses.
The FDA granted approval to olaratumab with doxorubicin combination treatment for patients with advanced soft tissue sarcoma (STS).
High-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) before surgey improves aerobic performance.
FDA approved atezolizumab treatment for non-small cell lung cancer (NSCLC) patients whose disease progressed during or following platinum-containing chemotherapy.
Topotecan-based triple-drug chemotherapy as a first line therapy can be used for patients with retinoblastoma.
Prostate cancer patients treated with testosterone-lowering drugs are more likely to develop dementia.
Bowel cancer patients with no psychological support after surgery, struggle with depression and poor well-being.
Ribociclib (CDK4/6 inhibitor) combined with letrozole improves by 44% the progression-free survival in postmenopausal women with hormone receptor positive advanced breast cancer.
Nintedanib (a multiple tyrosine kinase inhibitor) improves progression-free survival (PFS) in metastatic colorectal cancer.
The PARP inhibitor niraparib improves primary and secondary endpoints in platinum-sensitive recurrent ovarian cancer. Survival was significantly improved.
Nivolumab prolongs overall survival and reduces side effects in patients with relapsed metastatic head and neck cancer.
Overall survival in patients with stage 3 melanoma can be significantly increased with ipilimumab as adjuvant therapy.
Sunitinib can increase disease-free survival as adjuvant treatment for renal cell carcinoma after nephrectomy.
Atezolizumab, can prolong survival rate in patients with non-small-cell lung cancer regardless their PD-L1 expression.
Fulvestrant increases progression-free survival (PFS) in hormone receptor positive (ER+) advanced breast cancer patients.
Pembrolizumab can be the alternative option for first line treatment of patients with advanced lung cancer and high PD-L1 expression.
Immune check point inhibitors seem to be the suitable treatment for chemotherapy-ineligible patients with metastatic bladder cancer.
Immediate breast reconstruction (IBR) after mastectomy causes fewer breast cancer psychological side-effects, compared to delayed breast reconstruction (DBR).
Intensity-modulated radiation therapy (IMRT) causes less side effects in cervical and endometrial cancer than conventional radiotherapy (RT).
Brachytherapy alone can give similar results & fewer side-effects in mid-risk prostate cancer compared to its combination with external beam therapy (EBT).
Treating recurrent breast cancer with a 2nd lumpectomy and partial breast irradiation brings better results compared to conventional breast surgery.
Chemotherapy following radiotherapy can improve progression-free survival (PFS) in patients with follicular lymphoma.
Stereotactic radiation therapy used in patients with recurrent head and neck cancer can cause fewer side effects than traditional treatments.
Chemotherapy and radiation after surgery improves survival in adult patients with medulloblastoma.
European regulators have adopted a positive opinion for ixazomib capsules combined with lenalidomide and dexamethasone for the treatment of multiple myeloma.
Hypo-fractionated radiation has similar outcomes with conventional one for non-small lung cancer patients and milder side-effects, despite its shorter duration.
Stereotactic radiosurgery has shown better results in survival, less cognitive decline and better quality of life compared to whole brain radiotherapy.
A supplemental "boost" of radiation may reduce breast cancer recurrence in Ductal Carcinoma in Situ (DCIS) patients.
Cytoreductive surgery with targeted therapy improves survival rates in metastatic renal cell cancer patients.
Oncology trials show similar outcomes and side effects for early stage prostate cancer with conventional and hypo-fractionated radiotherapy.